Please assess the completion status of the following clinical trial:

Trial Title: Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed IBS diagnosis per Rome II for diagnosis of IBS.~* Colonoscopy within 2 years as part of IBS diagnostic evaluation.~* Has active symptoms of non-constipation IBS at baseline as measured by average daily scores for abdominal pain/discomfort, bloating, and stool consistency.~Exclusion Criteria:~* Symptoms of constipation.~* History of other gastrointestinal diseases.~* Type 1 or 2 diabetes.~* Lactose intolerance not controlled by lactose-free diet.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Subjects received placebo tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.
- Rifaximin (Type: EXPERIMENTAL): Subjects received rifaximin 550 mg tablets 3 times daily for 2 weeks and were followed for 10 weeks after completion of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).